Inflazyme Pharmaceuticals (T.IZP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sean Janzen who wrote (871)	4/9/1998 10:33:00 PM
From: Bob Schommer	Read Replies (1) of 1501

Sean: In your post #871 you floated up concerns that Barnes et al had on the potential inadvisability of prolonged disruption of NF-kB owing to concerns over immune function. How selective is Apanol in targeting a response and do you or others think these potential secondary effects may be a material stumbling block in a phase III experience? I've maintained a long-term-hold equity position with this company and am trying to better appreciate any risks up front. One of my reasons for initial optimism was the perceived prospect for somewhat higher odds (??) for negotiating through Phase III based on the fairly specific mechanism of action and negligible side effect profile that was seen (esp cf steroids). I realize these waters still have to be charted but I think you need to look ahead and try to get a pulse on the odds. I've been in ISIP from the early 90's on similar cross-over convictions and things are starting to pan out for them. Any thoughts you have regarding Apanol's impact on immune function would be appreciated. Regards, Bob

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next